MAP2K7 and thyroid cancer: In detail, PPARγ agonists, HDAC inhibitors, PI3K/AKT inhibitors and MEK/ERK inhibitors, have been recommended for NIS over-expression and have caused improved iodine uptake in thyroid cancers [121].